9 research outputs found
Psychological Well-Being of Parents of Very Young Children With Type 1 Diabetes – Baseline Assessment
Background: Type 1 diabetes in young children is a heavy parental burden. As part of
pilot phase of the KIDSAP01 study, we conducted a baseline assessment in parents to
study the association between hypoglycemia fear, parental well-being and child behavior.
Methods: All parents were invited to fill in baseline questionnaires: hypoglycemia fear
survey (HFS), WHO-5, Epworth Sleepiness Scale and Strength and Difficulties
Questionnaire (SDQ).
Results: 24 children (median age: 5-year, range 1-7 years, 63% male, mean diabetes
duration: 3 ± 1.7 years) participated. 23/24 parents filled out the questionnaires. We found
a higher score for the hypoglycemia fear behavior 33.9 ± 5.6 compared to hypoglycemia
worry 34.6 ± 12.2. Median WHO-5 score was 16 (8 - 22) with poor well-being in two
parents. Median daytime sleepiness score was high in five parents (>10). For six children a
high total behavioral difficulty score (>16) was reported. Pro social behavior score was
lower than normal in six children (<6). Parental well-being was negatively associated with
HFS total (r = - 0.50, p <.05) and subscale scores (r = - 0.44, p <.05 for HFS-Worry and
HFS-Behavior), child behavior (r = - 0.45, p = .05) and positively with child age and
diabetes duration (r = 0.58, p <.01, r = 0.6, p <.01). HFS, parental well-being nor daytime
sleepiness are associated with the HbA1c.
Conclusion: Regular screening of parental well-being, hypoglycemia fear and child
behavior should be part of routine care to target early intervention
Recommended from our members
Psychological Well-Being of Parents of Very Young Children With Type 1 Diabetes – Baseline Assessment
Background: Type 1 diabetes in young children is a heavy parental burden. As part of pilot phase of the KIDSAP01 study, we conducted a baseline assessment in parents to study the association between hypoglycemia fear, parental well-being and child behavior. Methods: All parents were invited to fill in baseline questionnaires: hypoglycemia fear survey (HFS), WHO-5, Epworth Sleepiness Scale and Strength and Difficulties Questionnaire (SDQ). Results: 24 children (median age: 5-year, range 1-7 years, 63% male, mean diabetes duration: 3 ± 1.7 years) participated. 23/24 parents filled out the questionnaires. We found a higher score for the hypoglycemia fear behavior 33.9 ± 5.6 compared to hypoglycemia worry 34.6 ± 12.2. Median WHO-5 score was 16 (8 - 22) with poor well-being in two parents. Median daytime sleepiness score was high in five parents (>10). For six children a high total behavioral difficulty score (>16) was reported. Pro social behavior score was lower than normal in six children (<6). Parental well-being was negatively associated with HFS total (r = - 0.50, p <.05) and subscale scores (r = - 0.44, p <.05 for HFS-Worry and HFS-Behavior), child behavior (r = - 0.45, p = .05) and positively with child age and diabetes duration (r = 0.58, p <.01, r = 0.6, p <.01). HFS, parental well-being nor daytime sleepiness are associated with the HbA1c. Conclusion: Regular screening of parental well-being, hypoglycemia fear and child behavior should be part of routine care to target early intervention
The challenge of long-term tetrahydrobiopterin (BH4) therapy in phenylketonuria: Effects on metabolic control, nutritional habits and nutrient supply
Background and aims: BH4-sensitive phenylketonuria (PKU) patients relax their phenylalanine (Phe) restricted diet due to increased Phe tolerance, while keeping dried blood Phe concentrations with in the therapeutic range. We aimed to investigate metabolic control, eating habits and nutrient supply under long-term BH4-therapy.
Patients and methods: Retrospective analysis of mean dried blood Phe concentrations and their variability, food and nutrient intake in BH4-sensitive patients (n = 8, 3f, age 6.0–16.6 y) under classical dietary treatment for one year and during the three years after initiation of BH4.
Results: Phe concentrations of BH4-sensitve PKU patients remained within therapeutic range throughout the observation period, independent of therapeutic regime. Under BH4, Phe tolerance increased significantly (493.2 ± 161.8 mg/d under classical diet vs 2021.93 ± 897.4 mg/d two years under BH4; P = 0.004). Variability of Phe concentrations remained unchanged (mean SD; P = 1.000). Patients adjust their food choice and significantly increased their intake of cereals, potatoes, dairy products and meat (P = 0.019, P = 0.016, P = 0.016 and P = 0.016, respectively). Under diet changes after implementation of BH4 a drop in micronutrient intake (vitamin D, folic acid, iron, calcium, iodine) could be revealed (P = 0.005, P < 0.001, P = 0.004, P = 0.001, P = 0.003, respectively).
Conclusions: BH4-sensitive PKU patients can achieve good metabolic control under an adjuvant BH4- or a BH4 monotherapy. The liberalized diet under BH4 seems to jeopardize the quality of patients' nutrition, and these patients require close follow-up and special nutrition education to minimize the risk for imbalanced diet and nutrient deficiencies
Recommended from our members
Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Very Young Children: A Multicenter, 3-Week, Randomized Trial.
OBJECTIVE: We aimed to assess the feasibility and safety of hybrid closed-loop insulin delivery in children with type 1 diabetes aged 1-7 years as well as evaluate the role of diluted insulin on glucose control. RESEARCH DESIGN AND METHODS: In an open-label, multicenter, multinational, randomized crossover study, 24 children with type 1 diabetes on insulin pump therapy (median age 5 years [interquartile range 3-6] and mean ± SD HbA1c 7.4 ± 0.7% [57 ± 8 mmol/mol] and total insulin 13.2 ± 4.8 units/day) underwent two 21-day periods of unrestricted living and we compared hybrid closed-loop with diluted insulin (U20) and hybrid closed-loop with standard strength insulin (U100) in random order. During both interventions, the Cambridge model predictive control algorithm was used. RESULTS: The proportion of time that sensor glucose was in the target range between 3.9 and 10 mmol/L (primary end point) was not different between interventions (mean ± SD 72 ± 8% vs. 70 ± 7% for closed-loop with diluted insulin vs. closed-loop with standard insulin, respectively; P = 0.16). There was no difference in mean glucose levels (8.0 ± 0.8 vs. 8.2 ± 0.6 mmol/L; P = 0.14), glucose variability (SD of sensor glucose 3.1 ± 0.5 vs. 3.2 ± 0.4 mmol/L; P = 0.16), or the proportion of time spent with sensor glucose 0.99). Total daily insulin delivery did not differ (17.3 ± 5.6 vs. 18.9 ± 6.9 units/day; P = 0.07). No closed-loop-related severe hypoglycemia or ketoacidosis occurred. CONCLUSIONS: Unrestricted home use of day-and-night closed-loop in very young children with type 1 diabetes is feasible and safe. The use of diluted insulin during closed-loop does not provide additional benefits compared with standard strength insulin.This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the grant agreement No 731560. This material reflects only the author’s views and the Commission is not liable for any use that may be made of the information contained therein. The Jaeb Center for Health Research is funded by JDRF under the grant 3-SRA-2016-297-M-N. Additional support for the artificial pancreas work was from National Institute for Health Research Cambridge Biomedical Research Centre, and Wellcome Trust Strategic Award (100574/Z/12/Z)
Recommended from our members
Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes.
OBJECTIVE: To evaluate the experiences of families with very young children aged 1 to 7 years (inclusive) with type 1 diabetes using day-and-night hybrid closed-loop insulin delivery. METHODS: Parents/caregivers of 20 children aged 1 to 7 years with type 1 diabetes completed a closed-loop experience survey following two 3-week periods of unrestricted day-and-night hybrid closed-loop insulin therapy using Cambridge FlorenceM system at home. Benefits, limitations, and improvements of closed-loop technology were explored. RESULTS: Responders reported reduced burden of diabetes management, less time spent managing diabetes, and improved quality of sleep with closed-loop. Ninety percent of the responders felt less worried about their child's glucose control using closed-loop. Size of study devices, battery performance and connectivity issues were identified as areas for improvement. Parents/caregivers wished for more options to input information to the system such as temporary glucose targets. CONCLUSIONS: Parents/caregivers of very young children reported important quality of life benefits associated with using closed-loop, supporting adoption of this technology in this population
Psychological Well-Being of Parents of Very Young Children With Type 1 Diabetes – Baseline Assessment
Background: Type 1 diabetes in young children is a heavy parental burden. As part of
pilot phase of the KIDSAP01 study, we conducted a baseline assessment in parents to
study the association between hypoglycemia fear, parental well-being and child behavior.
Methods: All parents were invited to fill in baseline questionnaires: hypoglycemia fear
survey (HFS), WHO-5, Epworth Sleepiness Scale and Strength and Difficulties
Questionnaire (SDQ).
Results: 24 children (median age: 5-year, range 1-7 years, 63% male, mean diabetes
duration: 3 ± 1.7 years) participated. 23/24 parents filled out the questionnaires. We found
a higher score for the hypoglycemia fear behavior 33.9 ± 5.6 compared to hypoglycemia
worry 34.6 ± 12.2. Median WHO-5 score was 16 (8 - 22) with poor well-being in two
parents. Median daytime sleepiness score was high in five parents (>10). For six children a
high total behavioral difficulty score (>16) was reported. Pro social behavior score was
lower than normal in six children (<6). Parental well-being was negatively associated with
HFS total (r = - 0.50, p <.05) and subscale scores (r = - 0.44, p <.05 for HFS-Worry and
HFS-Behavior), child behavior (r = - 0.45, p = .05) and positively with child age and
diabetes duration (r = 0.58, p <.01, r = 0.6, p <.01). HFS, parental well-being nor daytime
sleepiness are associated with the HbA1c.
Conclusion: Regular screening of parental well-being, hypoglycemia fear and child
behavior should be part of routine care to target early intervention
Psychological Well-Being of Parents of Very Young Children With Type 1 Diabetes – Baseline Assessment
Background: Type 1 diabetes in young children is a heavy parental burden. As part of
pilot phase of the KIDSAP01 study, we conducted a baseline assessment in parents to
study the association between hypoglycemia fear, parental well-being and child behavior.
Methods: All parents were invited to fill in baseline questionnaires: hypoglycemia fear
survey (HFS), WHO-5, Epworth Sleepiness Scale and Strength and Difficulties
Questionnaire (SDQ).
Results: 24 children (median age: 5-year, range 1-7 years, 63% male, mean diabetes
duration: 3 ± 1.7 years) participated. 23/24 parents filled out the questionnaires. We found
a higher score for the hypoglycemia fear behavior 33.9 ± 5.6 compared to hypoglycemia
worry 34.6 ± 12.2. Median WHO-5 score was 16 (8 - 22) with poor well-being in two
parents. Median daytime sleepiness score was high in five parents (>10). For six children a
high total behavioral difficulty score (>16) was reported. Pro social behavior score was
lower than normal in six children (<6). Parental well-being was negatively associated with
HFS total (r = - 0.50, p <.05) and subscale scores (r = - 0.44, p <.05 for HFS-Worry and
HFS-Behavior), child behavior (r = - 0.45, p = .05) and positively with child age and
diabetes duration (r = 0.58, p <.01, r = 0.6, p <.01). HFS, parental well-being nor daytime
sleepiness are associated with the HbA1c.
Conclusion: Regular screening of parental well-being, hypoglycemia fear and child
behavior should be part of routine care to target early intervention